Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Circulating carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP) levels were measured by radioimmunoassay in 53 patients with carcinoma of the ovary, 16 patients with other malignant genital tumors, and 31 women with nonmalignant diseases of the genital tract. The serum CEA concentration was elevated (greater than 5 ng/ml) in 11 patients with ovarian cancer, 2 patients with endometrial cancer, 1 patient with carcinoma of the cervix, and 1 patient with a benign embryonal cystic teratoma. Elevated CEA levels were found only in patients with advanced malignant disease, while early stages were associated with normal CEA concentrations. AFP levels were normal in all but 1 patient. Both CEA and AFP levels were markedly raised in a case of advanced genital carcinoma arising probably from the ovary. Ascitic fluid of another patient with ovarian cancer contained a high concentration of CEA, giving an identical reaction in immunodiffusion with CEA from colon cancer. The present results indicate that while the increased expression of carcinofetal components takes place in some malignant tumors of the female genital tract, it is usually a late phenomenon.
 ...
PMID:Carcinoembryonic antigen and alpha fetoprotein in malignant tumors of the female genital tract. 4 62

This study was designed to answer the question, do molecules with carcinoembryonic antigen (CEA) activity from colon, breast, and ovarian cancer differ? Extracts of two breast and three ovarian cancers with CEA activity were compared to three colon cancer CEA preparations and to the related antigen, colon carcinoma antigen-III, in terms of lectin- and antiserum-binding properties. With the use of Farr-type radioimmunoassays with the lectins, concanavalin A and wheat germ agglutinin, the iodinated colon CEA and CEA-like preparations from breast and ovarian cancer all showed distinctly different patterns of binding. Specificity of binding was confirmed by inhibition studies with the relevant monosaccharides. Similarly, with antisera prepared against colon CEA, colon carcinoma antigen-III, or breast CEA, it was shown that, although all preparations shared some antigens, unique antigenic determinants were also present on all preparations. These data are consistent with the concept of a series of closely related CEA and CEA-like molecules with distinct characteristics for each tissue source of CEA.
 ...
PMID:Evidence for common and distinct determinants of colon carcinoembryonic antigen, colon carcinoma antigen-III, and molecules with carcinoembryonic antigen activity isolated from breast and ovarian cancer. 6 90

The rationale and results of clinical use of carcinoembryonic antigen (CEA) tests in patients with carcinoma of the breast and colon deserve review. Plasma CEA levels have been found to correlate with the extent of tumor invasion and site of metastatic spread, and CEA titers have diagnostic and prognostic value. Although postresectional serial CEA testing is not as useful in cases of breast carcinoma, in cases of carcinoma of the colon it may indicate recurrence or progression of the lesion. However, there are limitations and CEA results should be interpreted in conjunction with other clinical information.
 ...
PMID:Carcinoembryonic antigen in patients with breast or colon cancer. 36 39

Charts of 437 patients having plasma carcinoembryonic antigen determinations during the period January 1, 1976 through April 30, 1976 were reviewed to determine whether CEA results led to clinical decisions altering management patterns. Data analysis disclosed that CEA test results did not result in any change in management in 167 patients with non-neoplastic disease. Most had single determinations. In 270 patients with neoplastic disease, CEA results led to changes in management in one patient with lung cancer and two patients with colon cancer, which may have altered prognosis. In a fourth patient, CEA results led to discovery of unresectable pancreatic cancer at laparotomy. Cost benefit analysis indicated a CEA test cost of $5,047.50 per patient benefitted in 299 patients eligible for analysis. We conclude that maximal benefit to the patient results from serial CEA test use in follow-up of colon cancer patients after curative therapy.
 ...
PMID:The use and abuse of CEA test in clinical practice. 41 1

The experience from the University of Minnesota with routine reoperations in cancers classified as Dukes' C suggests only a small minority of patients found to have asymptomatic recurrences will benefit from an additional operation. Also, morbidity and mortality will be significant. The presence of a rising carcinoembryonic antigen level following a potentially curative operation has been suggested as a more selective indicator for reoperation. Unfortunately, carcinoembryonic antigen levels are a far more sensitive indicator of hepatic metastases, the group usually not helped by operation. Patients with local-regional recurrent carcinoma of the colon and rectum--the group most likely to benefit from reoperation--often have normal carcinoembryonic antigen levels. The importance of patient selectivity for reoperation and the usefulness of the Astler-Coller staging system to define risk factors are stressed.
 ...
PMID:Carcinoembryonic antigen levels as an indicator for reoperation in patients with carcinoma of the colon and rectum. 45 23

Changes in peripheral lymphocyte counts have been reported in many different malignant conditions. We have studied 202 patients with carcinoma of the colon and rectum and have evaluated the relationship between peripheral lymphocytes and stage of disease as well as sex, location of tumor and carcinoembryonic antigen levels. We found a correlation between advancing stage of disease and lower levels of peripheral lymphocytes. An inverse relationship for carcinoembryonic antigen levels and lymphocyte values was also noted for the entire group as well as for individual Stages B anc C. It was suggested that the combination of both lymphocyte levels and carcinoembryonic antigen determinations might be useful as a prognostic indicator.
 ...
PMID:Peripheral lymphocytes in carcinoma of the colon and rectum. 50 46

Ferritin from malignant tissue differs electrophoretically from normal ferritin. The molecular basis of this difference has not yet been defined. Malignant tissue contains a mixture of ferritins from normal cells, inflammatory cells as well as cancer cells. GW-39 is a pure colon carcinoma cell system that synthesizes human carcinoembryonic antigen. Therefore, ferritin was isolated from normal colon mucosa and colon cancer tissues, as well as from the colon carcinoma cell line, to clarify the molecular relationship between normal and malignant ferritins. Colon carcinoma ferritin differs in primary structure from normal colon mucosal ferritin and contains at least six additional different tryptic peptides. These six peptides were also found in the ferritin from the colon carcinoma cell line. These data suggest that the alteration in ferritin structure occurs at the cellular level and is associated with the malignant state.
 ...
PMID:Alteration in tryptic peptide patterns of ferritins purified from human colon carcinoma. 50 93

Circulating levels of carcinoembryonic antigen (CEA) and glucose phosphate isomerase (GPI) have been measured and compared in 51 subjects with gastric and colonic diseases. Levels were higher in gastric and colonic cancer patients than in normals or patients with other diseases. Elevations of both these markers were most frequent in patients with metastases. Concentrations of CEA and GPI in gastrointestinal washings were also measured. No correlation was found between total protein content and concentrations of CEA or GPI in the washings. Further characterization of the perchloric acid-soluble material from colon washings by gel filtration indicated that the CEA-like substance from colon cancer patients was higher in molecular weight than standard radiolabeled CEA and CEA from normal colon washings. When tested against anti-CEA antiserum and pure CEA from a colonic cancer metastasis, all CEA preparations showed immunological identity in gel-diffusion plates; on immunoelectrophoresis similar mobility was indicative of a similar charge.
 ...
PMID:Quantitation and immunochemical characterization of carcinoembryonic antigen and glucose phosphate isomerase in blood and washings of patients with gastric and colonic diseases. 61 27

The indirect method of immunofluorescent analysis was applied to the study of the localization of the carcinoembryonic antigen (CEA) in pseudomucinous cystoma of the ovary and adenocarcinoma of the large intestine. CEA proved to be concentrated in the membranes and the basal part of the epithelial cells both in the pseudomucinous cystoma of the ovary and in the carcinoma of the large intestine.
 ...
PMID:[A comparative immunofluorescent study of carcino-embryonic antigen in pseudomucinous cystoma of the ovary and adenocarcinoma of the large intestine]. 76 54

A triple-bridge, indirect peroxidase-antiperoxidase method for demonstrating carcinoembryonic antigen (CEA) in frozen, ethanol-fixed or formalin-fixed, paraffin-embedded specimens was evaluated. Examination of 359 tissue specimens--234 malignant tumors, 37 benign neoplasms, 41 nonneoplastic diseased tissues, and 47 normal specimens--showed that CEA could usually be demonstrated in a group of cancers. We could detect CEA in carcinomas of the stomach, colon, rectum, pancreas, lung, and cervix. However, malignant tumors of the breast, prostate, kidney, larynx, brain, lymphoreticular system, soft tissues, and skin proved negative for CEA by the immunoperoxidase test. CEA could be detected in ethanol- or formalin-fixed sections. The only nonmalignant specimens showing CEA staining were a few benign tumors, the mucosae of some cases of colitis, and the resection margins of 2 cases of colon cancer; however, these were commonly very weak reactions. Measurement of tumor CEA content by radioimmunoassay revealed two causes for this relative specificity of the immunoperoxidase test for CEA:1) a quantitative difference existed in tissue CEA among the various specimens, and 2) the threshold for CEA staining in malignant specimens was usually above that in nonmalignant specimens. An analysis of the formalin-paraffin-treated sections showed that immunoperoxidase-tested CEA positivity reflected CEA levels in tissue of at least 3.0-5.0 mug/g; this permitted retrospective estimates of minimal tissue CEA concentrations in older histopathologic specimens by the immunoperoxidase reaction method. Formalin-paraffin-treated sections as old as 10 years still had demonstrable CEA. Although tumor CEA concentration correlated well with immunoperoxidase staining for CEA, plasma CEA titer did not necessarily reflect tumor CEA content. CEA positivity in primary and secondary tumors was strongly correlated; it was less strongly correlated with level of tumor differentiation.
 ...
PMID:Carcinoembryonic antigen in histopathology: immunoperoxidase staining of conventional tissue sections. 79 93


1 2 3 4 5 6 7 8 9 10 Next >>